252 related articles for article (PubMed ID: 29471850)
1. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
Zimran A; Wajnrajch M; Hernandez B; Pastores GM
Orphanet J Rare Dis; 2018 Feb; 13(1):36. PubMed ID: 29471850
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
Zimran A; Durán G; Giraldo P; Rosenbaum H; Giona F; Petakov M; Terreros Muñoz E; Solorio-Meza SE; Cooper PA; Varughese S; Alon S; Chertkoff R
Blood Cells Mol Dis; 2019 Sep; 78():14-21. PubMed ID: 27499018
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Elstein D; Paz A; Brill-Almon E; Chertkoff R
Blood Cells Mol Dis; 2015 Jan; 54(1):9-16. PubMed ID: 25453586
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
Zimran A; Durán G; Mehta A; Giraldo P; Rosenbaum H; Giona F; Amato DJ; Petakov M; Muñoz ET; Solorio-Meza SE; Cooper PA; Varughese S; Chertkoff R; Brill-Almon E
Am J Hematol; 2016 Jul; 91(7):656-60. PubMed ID: 27174694
[TBL] [Abstract][Full Text] [Related]
9. Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
Kuter DJ; Wajnrajch M; Hernandez B; Wang R; Chertkoff R; Zimran A
Blood Cells Mol Dis; 2020 May; 82():102418. PubMed ID: 32146279
[TBL] [Abstract][Full Text] [Related]
10. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
11. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
Grabowski GA; Golembo M; Shaaltiel Y
Mol Genet Metab; 2014 May; 112(1):1-8. PubMed ID: 24630271
[TBL] [Abstract][Full Text] [Related]
12. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS).
Titievsky L; Schuster T; Wang R; Younus M; Palladino A; Quazi K; Wajnrajch MP; Hernandez B; Becker PS; Weinreb NJ; Chambers C; Mansfield R; Taylor L; Tseng LJ; Kaplan P
Orphanet J Rare Dis; 2022 Apr; 17(1):145. PubMed ID: 35365177
[TBL] [Abstract][Full Text] [Related]
14. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
15. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.
Zimran A; Brill-Almon E; Chertkoff R; Petakov M; Blanco-Favela F; Muñoz ET; Solorio-Meza SE; Amato D; Duran G; Giona F; Heitner R; Rosenbaum H; Giraldo P; Mehta A; Park G; Phillips M; Elstein D; Altarescu G; Szleifer M; Hashmueli S; Aviezer D
Blood; 2011 Nov; 118(22):5767-73. PubMed ID: 21900191
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
17. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease.
Gupta P; Pastores GM
Pediatric Health Med Ther; 2017; 8():73-81. PubMed ID: 29388611
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
Abbas R; Park G; Damle B; Chertkoff R; Alon S
PLoS One; 2015; 10(6):e0128986. PubMed ID: 26053270
[TBL] [Abstract][Full Text] [Related]
20. Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa.
Zimran A; Dinur T; Revel-Vilk S; Akkerman EM; van Dussen L; Hollak CEM; Maayan H; Altarescu G; Chertkoff R; Maas M
J Inherit Metab Dis; 2018 Nov; 41(6):1259-1265. PubMed ID: 30066229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
